We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
Incyte Corporation (INCY)
After hours:
Chart Events
Performance Outlook
| Previous Close | 54.92 |
| Open | 54.72 |
| Bid | 53.84 x 300 |
| Ask | 53.92 x 100 |
| Day's Range | 53.76 - 55.00 |
| 52 Week Range | 50.27 - 75.74 |
| Volume | |
| Avg. Volume | 1,663,680 |
| Market Cap | 12.091B |
| Beta (5Y Monthly) | 0.67 |
| PE Ratio (TTM) | 20.32 |
| EPS (TTM) | 2.65 |
| Earnings Date | Apr 30, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 75.35 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for INCY
Related Research
- Incyte CorporationThe Argus Mid-Cap Model PortfolioSmall- and mid-cap stocks (SMID) have underperformed large-caps over the past 12 months, but may be in a better position to generate market-beating returns going forward. SMID companies tend to focus on domestic markets, so their businesses could be less disrupted by the fallout from global events. As well, the prices of SMID stocks generally are lower than the prices of large-caps. As well, there are long stretches in the record books when SMID stocks have outperformed large-caps. That said, SMID stocks can be risky. The standard deviation for monthly returns was 5.7% for SMID stocks over a 2003-2021 test period, versus 4.3% for large-caps. Still, despite the risks, diversified investors look to have exposure to small- and mid-caps based on the long-term performance record.RatingFair ValueEconomic Moat20 days agoArgus Research
ZacksWant Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Business WireIncyte to Report First Quarter Financial Results
WILMINGTON, Del., April 11, 2024--Incyte (Nasdaq:INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 30, 2024.
The Wall Street JournalBiotech Executive Who Bet on Rival’s Stock Committed Insider Trading, Jury Says
A biotech executive committed insider trading when he bet on a competitor’s stock, believing the shares would rise when news about his own company hit the market, a jury found Friday. The civil-fraud verdict against Matthew Panuwat, former head of business development for pharmaceutical company Medivation, marks a significant expansion of insider-trading law. The law has mostly been used to punish people who misuse nonpublic information by buying or selling their company’s stock before a big share-price move—or tipping others to do so.
Business WireIncyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
WILMINGTON, Del. and HONG KONG, April 01, 2024--Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
Insider Monkey12 Best S&P 500 Stocks To Buy According to Analysts
In this piece, we will take a look at the 12 best S&P 500 stocks to buy according to analysts. If you want to skip our coverage of the latest happenings surrounding one of America’s most widely followed stock indexes, then you can take a look at the 5 Best S&P 500 Stocks To Buy […]
Business WireIncyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WILMINGTON, Del., March 29, 2024--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ZacksMesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up
Mesoblast (MESO) gains as the FDA states that the available phase III data for lead candidate, remestemcel-L, is sufficient to support a regulatory filing for pediatric SR-aGVHD indication.
BloombergSEC Tests Insider-Trading Theory at Trial of Ex-Biotech Executive
(Bloomberg) -- A lawyer for the US Securities and Exchange Commission told a jury that a former biotech executive’s $120,000 windfall on a trade in a competing company’s stock was “like betting on a game when you know who’s going to win” because he knew the pending takeover of his firm would likely boost its rival.Most Read from BloombergTrump’s Net Worth Hits $6.5 Billion, Making Him One of World’s 500 Richest PeopleBiden Gains Ground Against Trump in Six Key States, Poll ShowsTrump Vows to Pay
Insider Monkey30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World. In the ever-evolving landscape of biotechnology, several companies like Novo Nordisk, Regeneron, and United […]
ZacksWhy Is Incyte (INCY) Up 1.8% Since Last Earnings Report?
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Morningstar Rating
Rating
Fair Value
Economic Moat
People Also Watch
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| BMRN BioMarin Pharmaceutical Inc. | |||
| VRTX Vertex Pharmaceuticals Incorporated | |||
| REGN Regeneron Pharmaceuticals, Inc. | |||
| ALNY Alnylam Pharmaceuticals, Inc. | |||
| EXEL Exelixis, Inc. |
Similar to INCY
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| BMRN BioMarin Pharmaceutical Inc. | |||
| ACAD ACADIA Pharmaceuticals Inc. | |||
| ALNY Alnylam Pharmaceuticals, Inc. | |||
| JAZZ Jazz Pharmaceuticals plc | |||
| EXEL Exelixis, Inc. |
Analyst Price Targets (17)
Upgrades & Downgrades
| Reiterates | RBC Capital: Sector Perform to Sector Perform | 3/25/2024 | |
| Maintains | B of A Securities: Neutral to Neutral | 3/13/2024 | |
| Reiterates | Stifel: Hold to Hold | 3/12/2024 | |
| Reiterates | RBC Capital: Sector Perform to Sector Perform | 3/12/2024 | |
| Initiated | Jefferies: to Buy | 2/23/2024 | |
| Downgrade | JMP Securities: Market Outperform to Market Perform | 2/14/2024 |
Company Profile
1801 Augustine Cut-Off
Wilmington, DE 19803
United States
302 498 6700
https://www.incyte.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 2,524
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
